BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, today announced the successful acquisition of BioDuro's drug product development and ...

Through a combination of high-pressure experiments and optical spectroscopy, physicists have revealed new insights into the ...

A survey of pediatricians found 35 such drugs that urgently need child-friendly oral liquid formulations, noted research team leader Federico Harte, professor of food science and research team leader.

Onyx Scientific expands material science capabilities as part of 25th anniversary milestone  Sunderland, 19th January, 2026 – Onyx Scientific has announced the expansion of its solid form and material ...

Bausch Health’s RED-C phase 3 clinical programme of amorphous-rifaximin SSD in adults with liver cirrhosis for primary prevention of HE fails to meet primary endpoint: Laval, Ca ...

Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap the molecule’s development.

Many drugs that children need are not available in liquid form, which makes them difficult or unsafe to administer orally to ...

The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in ...

Canadian pharma company Bausch Health has announced the results of the global Phase III RED-C clinical program.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3 RED-C clinical program ...

A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...

Shares of Bausch Health (NYSE:BHC) dropped about 8% in early trading on Friday after the company disclosed unsuccessful ...